Insights on PORTEC 4A Trial Results for Endometrial Cancer

In this podcast episode, hear from lead author Anne Sophie Van den Heerik as she discusses the PORTEC 4A trial, the first trial to prospectively investigate a molecular integrated risk profile in patients with high-intermediate risk endometrial cancer. Listeners will learn how PORTEC data informs real-world clinical choices, what the results mean for radiation techniques and toxicity reduction, and how ongoing research continues to refine the role of adjuvant therapy. This podcast is moderated by Pearly Khaw (Australia).